Setogepram sodium salt Inhibitor

Name: Setogepram sodium salt Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753649
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753649

Setogepram sodium salt is an orally active GPR40 agonist and is an antagonist or inverse agonist for GPR84, with anti-fibrotic, anti-inflammatory and anti-proliferative actions. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Setogepram sodium salt, Inhibitor

Full Product Name

Setogepram sodium salt

Product Synonym Names

PBI-4050 sodium salt

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

228.26

Solubility

H2O: 100mg/mL (438.10mM)
DMSO: 64mg/mL (280.38mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C13H17NaO2

SMILES

O=C(O[Na])CC1=CC(CCCCC)=CC=C1

CAS Number

1254472-97-3

Target & IC50

GPR40

Product Categories/Family for Setogepram sodium salt, inhibitor

Endocrinology/Hormones; GPR

Product References and Citations for Setogepram sodium salt, inhibitor

Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365.
Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3(10). pii: 120365.
Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81.
Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367(1):71-81.

Other Notes

Small volumes of Setogepram sodium salt, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Setogepram sodium salt purchase

MBS5753649 is an inhibitor targeting Setogepram sodium salt.